Main Article Content
Introduction: Most of avoidable defibrillator therapies can be reduced by evidence-based programming, but defining tachycardia configurations across all device manufacturers is not straightforward.
Aims: To determine if a uniform programming of tachycardia zones, independently of the manufacturer, result in a lower rate of avoidable shocks in primary-prevention heart failure (HF) patients and also if programming high-rate or delayed therapies can have some benefit.
Methods: Prospective cohort with historical controls. HF patients with a primary-prevention indication for a defibrillator were randomized to receive one of two new programming configurations (high-rate or delayed therapies). A historical cohort of patients with conventional programming was analyzed for comparison. The primary endpoint was any therapy [shock or anti-tachycardia pacing (ATP)] delivered. Secondary endpoints were appropriate shocks, appropriate ATP, appropriate therapies, inappropriate shocks, syncope and death.
Results: 89 patients were assigned for new programming group [high rate (n=47) or delayed therapy (n=42)]. They were compared with 94 historical patients with conventional programming. During a mean follow-up of 20±7 months, the new programming was associated with a reduction in any therapy (HR = 0.265, 95% CI 0.121-0.577, p=0.001), even after adjustment. Aproppriate ATP and any shock were also reduced. Syncope did not occur. Sudden, cardiovascular and all-cause deaths were not different between the groups. In the new programming group, neither highrate nor delayed programming were better than the other.
Conclusions: In our study, programming tachycardia zones homogeneously across all manufacturers was possible and resulted in a lower rate of therapies, shocks and appropriate ATP.
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
2 Schrage B, Uijl A, Benson L et al. Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry. Circulation. 2019;140(19):1530-1539. doi: 10.1161/CIRCULATIONAHA.119.043012.
3 EU-CERT-ICD study, presented in ESC Congress 2019 and EHRA Webinar “Do ICDs still save lives in modern heart failure patients? New lessons from ESC Congress 2019”, 10/02/2020. Link: https://www.escardio.org/Education/E-Learning/Webinars/Do-ICD-still-save-lives-in-modern-heart-failure-patients
4 Gasparini M, Proclemer A, Klersy C et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013; 309:1903–1911. doi: 10.1001/jama.2013.4598.CrossrefMedlineGoogle Scholar
5Moss A, Schuger C, Beck C et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012; 367:2275–2283. doi: 10.1056/NEJMoa1211107.CrossrefMedlineGoogle Scholar
6 Ruwald A, Schuger C, Moss AJ et al. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circ Arrhythm Electrophysiol. 2014; 7:785–792. doi: 10.1161/CIRCEP.114.001623.LinkGoogle Scholar
7 Saeed M, Hanna I, Robotis D et al. Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study. J Cardiovasc Electrophysiol. 2014; 25:52–59. doi: 10.1111/jce.12273.CrossrefMedlineGoogle Scholar
8 Wilkoff B, Ousdigian K, Sterns L, Wang Z, Wilson R, Morgan J. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol. 2006; 48:330–339. doi: 10.1016/j.jacc.2006.03.037.CrossrefMedlineGoogle Scholar
9 Wilkoff B, Williamson B, Stern R et al. PREPARE Study Investigators. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008; 52:541–550. doi: 10.1016/j.jacc.2008.05.011.CrossrefMedlineGoogle Scholar
10 Gasparini M, Menozzi C, Proclemer A et al. A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection window programming in patients with LEft VentriculAr dysfunction, Non-ischemic eTiology in primary prevention treated with a biventricular ICD] study. Eur Heart J. 2009; 30:2758–2767. doi: 10.1093/eurheartj/ehp247.CrossrefMedlineGoogle Scholar
11 Tan V, Wilton S, Kuriachan V, Sumner GL, Exner DV. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014; 7:164–170. doi: 10.1161/CIRCEP.113.001217.LinkGoogle Scholar.
12 Wilkoff B, Fauchier L, Stiles MK et al. HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace. 2016 Feb;18(2):159-83. doi: 10.1093/europace/euv411
13 Thøgersen A, Larsen J, Johansen J, Abedin M, Swerdlow C. Failure to Treat Life-Threatening Ventricular Tachyarrhythmias in Contemporary Implantable Cardioverter-Defibrillators: Implications for Strategic Programming. Circ Arrhythm Electrophysiol. 2017 Sep;10(9). pii: e005305. doi: 10.1161/CIRCEP.117.005305.
14 Stiles M, Fauchier L, Morillo C et al. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace. 2019 Sep 1;21(9):1442-1443. doi: 10.1093/europace/euz065.
15 Gradaus R, Bode-Schnurbus L, Weber M et al. Effect of ventricular fibrillation duration on the defibrillation threshold in humans. Pacing Clin Electrophysiol 2002;25: 14–9.
16 Gulizia M, Piraino L, Scherillo M et al. A randomized study to compare ramp versus burst antitachycardia pacing therapies to treat fast ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators: the PITAGORA ICD trial. Circ Arrhythm Electrophysiol. 2009 Apr;2(2):146-53. doi: 10.1161/CIRCEP.108.804211.
17 Wathen M, DeGroot P, Sweeney M et al. Prospective Randomized Multicenter Trial of Empirical Antitachycardia Pacing Versus Shocks for Spontaneous Rapid Ventricular Tachycardia in Patients With Implantable Cardioverter-Defibrillators - Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) Trial Results. Circulation. 2004 Oct 26;110(17):2591-6. Epub 2004 Oct 18.
18 Peters R, Zhang X, Gold M. Clinical predictors and efficacy of antitachycardia pacing in patients with implantable cardioverter defibrillators: the importance of the patient’s sex. Pacing Clin Electrophysiol. 2001;24:70–4.
19 Gillis A, Leitch J, Sheldon R, et al. A prospective randomized comparison of autodecremental pacing to burst pacing in device therapy for chronic ventricular tachycardia secondary to coronary artery disease. Am J Cardiol. 1993;72:1146–51.
20 Dallaglio P, Anguera I, Martínez J et al. Shock Reduction With Antitachycardia Pacing Before and During Charging for Fast Ventricular Tachycardias in Patients With Implantable Defibrillators. Rev Esp Cardiol (Engl Ed). 2018 Sep;71(9):709-717. doi: 10.1016/j.rec.2017.11.003. Epub 2017 Dec 11.
21 Sears S, Todaro J, Urizar G, et al. Assessing the psychosocial impact of the ICD: a national survey of implantable cardioverter defibrillator health care providers. Pacing Clin Electrophysiol 2000;23:939 – 45.
22 Lüderitz B, Jung W, Deister A, Marneros A, Manz M. Patient acceptance of the implantable cardioverter defibrillator in ventricular tachyarrhythmias. Pacing Clin Electrophysiol 1993;16:1815–21.
23 Kober L, Thune J, Nielsen J et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med 2016; 375:1221-30.
24 Moss A, Zareba W, Hall W et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883
25 Desai A, Fang J, Maisel W et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004; 292:2874–2879.
26 Bardy G, Lee K, Mark D et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med 2005; 352:225–237.
27 Greene S, Fonarow G, DeVore A et al. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019 May 21;73(19):2365-2383. doi: 10.1016/j.jacc.2019.02.015.
28 Le H, El-Khatib C, Mombled M et al. Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016 18;11(2):e0145958. doi: 10.1371/journal.pone.0145958. eCollection 2016.